|
Neonatal Intensive Care Drug Manual
|
| bet | 77/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Administration
|
Oral: Shake well before use. May be given with or without feed.
IV: Infuse over at least 1 hour.
|
Monitoring
|
During infusion – heart rate and blood pressure.
IV site for signs of phlebitis.
Liver function.
|
Contraindications
|
Hepatic dysfunction with prior azithromycin therapy.
Concomitant therapy with QT interval prolonging drugs (e.g. cisapride)
|
Precautions
|
Hepatic dysfunction.
IV solutions of a concentration greater than 2 mg/mL may cause local infusion-site reactions.
|
Drug Interactions
|
Drugs that can prolong QT interval.
Digoxin – may result in digoxin toxicity.
|
Adverse Reactions
|
Common: Nausea, vomiting, abdominal pain and diarrhoea (all less than erythromycin).
Rare: Hypertrophic pyloric stenosis, thrombophlebitis (after IV administration), ventricular dysrhythmias (after IV administration). In general, the risk of dysrhythmias is increased when these agents are administered in combination with other drugs that prolong the QT interval. Increased liver enzymes, hepatitis, hepatic necrosis, hypersensitivity reactions.
|
Compatibility
|
Fluids: Glucose 5%, glucose 5% in sodium chloride solutions, Hartmann’s, sodium chloride 0.9%, sodium chloride 0.45%
Y-site : Bivalirudin, ceftaroline fosamil, dexmedetomidine, tigecycline
|
|
|
| |
